Aligos Therapeutics在HEP DART 2019上展示了基于组合的方法来治疗慢

StephenW

Aligos Therapeutics Presents Combination-Based Approach for Treating Chronic Hepatitis B (CHB) at HEP DART 2019
Oral Presentation on Combination Therapy Targeting CHB
Email Print Friendly Share
December 10, 2019 15:00 ET | Source: Aligos Therapeutics

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Aligos Therapeutics, a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced that chief executive officer Larry Blatt will deliver an invited oral presentation at HEP DART 2019 held on December 8 – 12, in Kauai, Hawaii.

Titled “Combination approaches towards a functional cure for chronic hepatitis B,” today’s presentation will detail Aligos’ overarching approach in developing multiple candidates to target clinically validated mechanisms for inhibiting the hepatitis B virus (HBV) life cycle, which comprise capsid assembly modulators (CAMs), S-antigen transport-inhibiting oligonucleotide polymers (STOPS™) and antisense oligonucleotides (ASOs).

“One key marker of functional cure in CHB is durable hepatitis B surface antigen (HBsAg or S-antigen) loss following treatment, which is currently lacking in the CHB therapeutic space,” said Aligos chief executive officer Lawrence Blatt, Ph.D., MBA. “Considering that a triple combination therapy is likely required to achieve high rates of functional cure, we have targeted essential components of the HBV life cycle, which include S-antigen secretion, genome replication and maintenance and viral transcription and translation. Aligos is developing a combination therapy including CAMs, STOPs and ASOs, each targeting one or more clinically validated pathways necessary for viral replication.”

Blatt continued, “We see an outstanding need in CHB for treatment regimens that are optimized for delivery, target engagement and safety. Our CAM candidate, ALG-000184, has picomolar potency and excellent oral pharmacokinetic properties, our STOP candidate, ALG-010133, can be delivered via subcutaneous administration and demonstrates the most potent in vitro anti-S-antigen activity to date. Our two-trigger ASO candidates target two conserved transcripts in HBV, providing an increased resistance barrier and better viral genotype coverage. These drug candidates are poised to deliver a best-in-class combination regimen resulting in high rates of functional cure for CHB.”

StephenW

Aligos Therapeutics在HEP DART 2019上展示了基于组合的方法来治疗慢性乙型肝炎（CHB）
针对CHB的联合疗法的口头报告
电子邮件打印友好分享
美国东部时间2019年12月10日15:00 |资料来源：Aligos Therapeutics

2019年12月10日，加利福尼亚州南旧金山-全球领先的临床前生物技术公司Aligos Therapeutics公司致力于开发针对肝病和病毒感染的靶向疗法，包括慢性乙型肝炎（CHB），非酒精性脂肪性肝炎（NASH）和肝细胞癌（HCC）今天宣布，首席执行官拉里·布拉特（Larry Blatt）将于12月8日至12日在夏威夷考艾岛举行的HEP DART 2019上进行邀请性的口头报告。

今天的演讲标题为“用于慢性乙型肝炎功能性治疗的组合方法”，将详细介绍Aligos在开发多种候选药物时的总体方法，以靶向抑制乙肝病毒（HBV）生命周期的临床验证机制，其中包括衣壳装配调节剂（CAMs） ），抑制S抗原转运的寡核苷酸聚合物（STOPS™）和反义寡核苷酸（ASO）。

Aligos首席执行官Lawrence Blatt博士说：“ CHB功能性治愈的一个关键标志是治疗后持久性乙型肝炎表面抗原（HBsAg或S抗原）的流失，目前在CHB的治疗领域尚缺乏这种能力。”工商管理硕士“考虑到可能需要三联疗法来实现高水平的功能治愈，我们针对了HBV生命周期的基本组成部分，包括S抗原分泌，基因组复制和维持以及病毒转录和翻译。 Aligos正在开发一种包括CAM，STOP和ASO在内的组合疗法，它们各自针对病毒复制所必需的一种或多种经过临床验证的途径。”

Blatt继续说道：“我们看到CHB迫切需要针对交付，目标参与和安全性进行优化的治疗方案。我们的CAM候选药物ALG-000184具有皮摩尔效价和出色的口服药代动力学特性，我们的STOP候选药物ALG-010133可以通过皮下给药来给药，显示了迄今为止最有效的体外抗S抗原活性。我们的两次触发式ASO候选物靶向HBV中两个保守的转录本，从而提供了更高的抗性屏障和更好的病毒基因型覆盖率。这些候选药物有望提供一流的联合治疗方案，从而实现CHB的高功能治愈率。”